141763-48-6

Basic information

• Product Name: 3-(3-iodophenyl)-1-propanol
• Synonyms: 3-(3-iodophenyl)-1-propanol
• CAS NO: 141763-48-6
• Molecular Weight: 262.09
• Mol File: 141763-48-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3-(3-iodophenyl)-1-propanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-iodophenyl)-1-propanol(141763-48-6)
• EPA Substance Registry System: 3-(3-iodophenyl)-1-propanol(141763-48-6)

Safety Data

• Hazardous Substances Data: 141763-48-6(Hazardous Substances Data)

Upstream product

• 121269-65-6 ethyl 3-(3-iodophenyl)propanoate 
• 1597430-75-5 C₁₄H₁₇IO₄ 
• 49617-83-6 m-Iodobenzyl bromide 
• 68034-75-3 3-(3-iodophenyl)propanoic acid 

Downstream Products

• 1597430-57-3 C₁₈H₂₂IN₃O₆ 
• 1597430-41-5 3-(3-iodophenyl)propyloxyamine hydrochloride 
• 1597430-76-6 1-(3-bromopropyl)-3- iodobenzene 
• 1222138-52-4 3-[3-[5-[[1-(tert-butoxycarbonyl)-2(R)-azetidinyl]methoxy]-3-pyridyl]phenyl]-1-propanol 
• 1222138-45-5 3-[3-[5-[[1-(tert-butoxycarbonyl)-2(S)-pyrrolidinyl]methoxy]-3-pyridyl]phenyl]-1-propanol 
• 1222138-21-7 3-[3-[5-[[1-(tert-butoxycarbonyl)-2(S)-azetidinyl]methoxy]-3-pyridyl]phenyl]-1-propanol 
• 745078-91-5 5-(3-(3-Hydroxy-propyl)-phenyl)-isoxazole-3-carboxylic Acid Ethyl Ester 

Relevant articles and documents

Stapled Peptides by Late-Stage C(sp3)?H Activation

Despite the importance of stapled peptides for drug discovery, only few practical processes to prepare cross-linked peptides have been described; thus the structural diversity of available staple motifs is currently limited. At the same time, C?H activati

4-alkyloxyimino derivatives of uridine-5′-triphosphate: Distal modification of potent agonists as a strategy for molecular probes of P2Y 2, P2Y4, and P2Y6 receptors

Extended N4-(3-arylpropyl)oxy derivatives of uridine-5′-triphosphate were synthesized and potently stimulated phospholipase C stimulation in astrocytoma cells expressing G protein-coupled human (h) P2Y receptors (P2YRs) activated by UTP (P2Y2/4R) or UDP (P2Y6R). The potent P2Y4R-selective N4-(3- phenylpropyl)oxy agonist was phenyl ring-substituted or replaced with terminal heterocyclic or naphthyl rings with retention of P2YR potency. This broad tolerance for steric bulk in a distal region was not observed for dinucleoside tetraphosphate agonists with both nucleobases substituted. The potent N 4-(3-(4-methoxyphenyl)-propyl)oxy analogue 19 (EC50: P2Y2R, 47 nM; P2Y4R, 23 nM) was functionalized for chain extension using click tethering of fluorophores as prosthetic groups. The BODIPY 630/650 conjugate 28 (MRS4162) exhibited EC50 values of 70, 66, and 23 nM at the hP2Y2/4/6Rs, respectively, and specifically labeled cells expressing the P2Y6R. Thus, an extended N4-(3- arylpropyl)oxy group accessed a structurally permissive region on three G q-coupled P2YRs, and potency and selectivity were modulated by distal structural changes. This freedom of substitution was utilized to design of a pan-agonist fluorescent probe of a subset of uracil nucleotide-activated hP2YRs.

Protein-tyrosine phosphatase inhibitors and uses thereof

The present invention is directed to compounds of formula (I), or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.